Lycia Therapeutics, a biotech company developing therapies targeting disease-causing proteins, priced its upsized initial public offering at $18 per share, raising approximately $317.5 million before expenses. The company plans to use the funds to advance its LYTAC platform focused on autoimmune and allergic diseases. Lycia's stock will begin trading on Nasdaq under the symbol LYCA on October 23, 2026. The offering includes an option for underwriters to buy additional shares, with closing expected on October 26, 2026, pending customary conditions.
Lycia Therapeutics' upsized IPO raised approximately $317.5 million before expenses, priced at $18 per share. For readers following the health sector, here is Pluang's market snapshot as of Oct 23, 2026 05:32 WIB: out of 150 priced health-sector US stocks, 85 rose and 64 fell today. Notable movers include CTXR at USD 0.37 with a 1-day change of -6.42% and 100% buy order activity, INO at USD 0.84 up 5.76% with 73% sell order activity, and SNN at USD 30.85 up 5.54%, with a typical hold time of 122 days on Pluang.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Alkane Resources generated A$102 million in mine operating cash flow and produced 40,740 gold equivalent ounces in the September quarter, supported by its three mines in Australia and Sweden. The company reported A$459 million in cash, bullion, and i...
